Rare Daily Staff
The global contract development and manufacturing organization Vibalogics said it has initiated phase I of its planned $150 million investment in a late-phase clinical and commercial virotherapy manufacturing facility near Boston, Massachusetts.
The three-year investment plan includes the build out of a 110,000 square foot-facility totaling $150 million across redevelopment, equipment and personnel. The facility is expected to create 100 jobs initially, reaching 250 employees in the next four years.
The CDMO, which specializes in the production of oncolytic viruses, viral vector vaccines, and viral vector gene therapy products, expects the site to be operational by the second half of 2021.
“The site will provide a complete suite of virotherapy services to support drug developers and their most revolutionary products,” said Vibalogics’ CEO Tom Hochuli. “The addition of a late stage clinical and commercial facility means we can easily tech transfer our customers’ products from our early phase manufacturing facility in Germany to the U.S., resulting in a complete end-to-end service from pre-clinical to commercial supply.”
The company was recently selected by Janssen Pharmaceutical Companies, a division of Johnson & Johnson, as one of its manufacturing partners for its investigational COVID-19 vaccine candidate.
In May 2019, Vibalogics was acquired by Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector, allowing the CDMO to further its growth strategy and fast-track its plans to extend its footprint in the United States.
Photo: Vibalogics’ CEO Tom Hochuli
Stay Connected
Sign up for updates straight to your inbox.